Nasdaq GlobeNewswire

Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency

Del

WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit.

"The MAA filing represents a significant milestone for Tetraphase as it is our first regulatory application for marketing authorization and a major step toward making eravacycline available as a new antibiotic treatment option for patients with serious hospital infections," said Guy Macdonald, President and Chief Executive Officer of Tetraphase. "I am proud of the dedicated team at Tetraphase who made this  happen and who support our commitment to develop novel antibiotics to treat drug-resistant infections. We look forward to working with the EMA during their review of this application and to focusing on the submission of the New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2018."

About Eravacycline

Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens that have been highlighted as urgent public health threats by both the World Health Organization and the U.S. Centers for Disease Control (CDC). Eravacycline has demonstrated potent activity against multidrug-resistant (MDR) pathogens, including carbapenem-resistant enterobacteriaceae (CRE), Acinetobacter baumannii, and colistin-resistant bacteria carrying the mcr-1 gene.  Eravacycline is in phase 3 clinical development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

Eravacycline is currently being investigated in the Company's phase 3 IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) program. To date, eravacycline has been administered to over 1,500 patients and in two completed phase 3 trials in cIAI. In IGNITE1, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem, was well tolerated, and achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. The IGNITE1 data is serving as the basis of the MAA for IV eravacycline for the treatment of patients with cIAI now under review by the EMA. In IGNITE4, a second phase 3 clinical trial in patients with cIAI, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem, was well tolerated, and achieved high cure rates. The Company plans to use the results from IGNITE1 and IGNITE4 to support an NDA submission for IV eravacycline in cIAI. Tetraphase is also currently conducting IGNITE3, an additional phase 3 trial evaluating once-daily IV eravacycline in patients with cUTI and, assuming a positive outcome, the Company plans to use the results from IGNITE3 to support a supplemental NDA submission for eravacycline in cUTI. In parallel, Tetraphase is continuing its efforts to develop an oral dose formulation of eravacycline. A phase 1 clinical program is ongoing which is designed to evaluate and optimize the oral dosing regimen for eravacycline.

About Complicated Intra-abdominal Infections (cIAI)
Intra-abdominal infection (IAI) is a common problem in clinical practice and comprises a wide variety of disease processes. IAI is classified as uncomplicated or complicated based on the extent of the infection. Complicated intra-abdominal infection extends beyond the source organ into the peritoneal space (the space between the two membranes that separate the organs in the abdominal cavity from the abdominal wall) as a result of perforation or other damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. Different bacterial pathogens are responsible for cIAI, including Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria, and there are also mixed infections. IAI is an important cause of morbidity and mortality and is the second most common cause of infectious mortality in the intensive care unit. Early detection, containment and appropriate antimicrobial treatment are essential to the successful treatment of IAI. This is even more critical with increasing rates of infections caused by drug-resistant bacteria, which limit the effectiveness of currently available antibiotics.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.

Forward-Looking Statements

Any  statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including: whether results obtained in  previous clinical  trials will be indicative of results obtained in future clinical trials; whether eravacycline  or any other clinical candidate will advance through the clinical trial process on a timely basis or at all; whether the results of the Company's development efforts will warrant regulatory submission and whether any such submissions will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if any clinical candidate obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 2, 2017. In addition, the forward-looking statements included in this press release represent our views as of August 17, 2017. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some  point in the future, we specifically disclaim any obligation to do so.

Investor Contacts: 
Tetraphase Pharmaceuticals 
Teri Dahlman
617-600-7040
tdahlman@tphase.com

Argot Partners 
Maeve Conneighton 
206.899.4940
maeve@argotpartners.com

Media Contact: 
Sam Brown Inc.
Mike Beyer
312-961-2502
Mikebeyer@sambrown.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tetraphase Pharmaceuticals via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Airtel and Cisco Team to Improve Mobile User Experience25.2.2018 12:00Pressemelding

Utilizing Cisco's Self-Optimizing Network solutions to manage and support the massive growth in data and voice traffic BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - With mobile data consumption surpassing usage of the U.S. and China in 20171, mobile service providers in India are working to enhance their network infrastructure to manage and support the growth surge and ensure quality of customer experience. Bharti Airtel (Airtel), India's largest telecommunications services provider, and Cisco have joined forces to improve customer experience by taking their SON collaboration to next level. SON is now carrying out optimization based on customer experience and predictive analytics apart from the traditional approach of responding to network degradations. SON self-healing applications have been enriched for taking proactive actions in near real time, using predictive machine learning and interworking of SON with NOC tools, PM analytics & customer experience

Cisco Spearheads Multi-Vendor Open vRAN Ecosystem Initiative For Mobile Networks25.2.2018 12:00Pressemelding

First ecosystem of its kind brings together innovators including Reliance Jio, Altiostar, Aricent, Intel, Mavenir, Phazr, Red Hat, and Tech Mahindra BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Mobile network operators are facing strong pressures to evolve their businesses and operations for profitable growth and differentiation. Explosive demand for bandwidth persists, while ARPU pressures mount due to competition and limited service innovation. Addressing these challenges requires industry innovation focused on delivering new revenue-generating services based on a more flexible and agile service delivery environment, while reducing Capex and Opex. Innovations such as network function virtualization have laid the groundwork for a new fundamental architecture to emerge. While many functions of a mobile network are being virtualized, including the Evolved Packet Core (EPC), IP Multimedia Subsystems (IMS), the Gateway Internet LAN (Gi-LAN) and data transpor

TIM and Cisco Join Forces To Increase The IT Security Of Italian Companies25.2.2018 12:00Pressemelding

TIM Safe Web, the new security service developed in collaboration with Cisco and integrated into the TIM network, going live in March BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Starting from March, TIM, the leading provider of mobile and fixed telecommunication services in Italy, in partnership with Cisco will offer "TIM Safe WEB", a highly secure platform service, integrated in the TIM network, able to safeguard small business users from malware, such as ramsomware, phishing, and other malicious cybersecurity activities. TIM Safe Web combines TIM's unique technologies and information with the capabilities of the Cisco Umbrella cloud-based security platform, which leverages a constantly updated global database of threat intelligence. This "over-the-network" service enhancement will be provided to about 600.000 TIM Business customers in order to improve both security and quality of service starting from small business market that is very exposed to cyber

Cisco Launches New '5G Now' Portfolio for Service Providers Taking Action Today25.2.2018 12:00Pressemelding

More than 20 global service provider and mobile operator customers worldwide are advancing their 5G action plans with Cisco BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Continuing on its path to disrupt the industry by redefining the network, Cisco announced today its '5G Now' portfolio for service providers ready to go full throttle on their 5G roadmap. 5G services promise to offer emerging new services at significantly faster speeds, expanded capacity and stronger coverage to accommodate the more than 27 billion connected devices1 expected on service provider networks by 2021. Beginning 2020, 5G connections will grow more than a thousand percent from 2.3 million in 2020 to over 25 million in 20212. At Mobile World Congress this week, many technology vendors are focused on the spectrum advantages, radio equipment and architecture to support 5G services. Cisco is committed to showing service providers and mobile operators why 5G is important to plan for,

Cisco and TIM: Together to Accelerate Italy's Digitization25.2.2018 12:00Pressemelding

BARCELONA, Spain, Feb. 25, 2018 (GLOBE NEWSWIRE) -- Mobile World Congress - Cisco and TIM, the leading service provider in Italy, announced a major agreement aimed at accelerating Italy's digitization today at Mobile World Congress. The two companies are engaged in developing a joint business and innovation program. They will leverage their unique competences and technologies, to create next generation solutions and services focused in particular on Cybersecurity, Internet of Things, Industry 4.0, Smart Cities and 5G. This Memorandum of Understanding (MOU) has been signed in the framework of Digitaliani, the three-year investment plan launched by Cisco in January 2016, whose objectives are well aligned with TIM own digitization program. The partnership is based on three pillars. Sharing competences and solutions for the digital transformation of companies, public sector and services targeted to citizens A common effort to develop a partner ecosystem able to leverage the new opportuniti

Valero to Purchase SemLogistics Milford Haven Fuel Storage Facility23.2.2018 22:15Pressemelding

LONDON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Valero Logistics UK Ltd, a subsidiary of Valero Energy Corporation (NYSE:VLO), and SemGroup Europe Holding L.L.C., a SemGroup Corporation company, have today signed an agreement for the purchase of SemLogistics Milford Haven fuel storage facility on the west coast of Wales. Situated across the Haven from Valero's refinery at Pembroke, the facility is one of the largest petroleum products storage facility in the United Kingdom (UK) with 8.5 million barrels of capacity for storing gasoline, gasoline blendstocks, naphtha, jet fuel, gas oil, diesel, and crude oil. Over 67 percent of the storage capacity is multiproduct or dual purpose, giving Valero the flexibility to meet customers' demands in the UK and throughout Northwest Europe. Additionally, Milford Haven will continue to operate as a third-party storage facility, offering storage options for third party customers across the European petroleum markets. "This facility complements our Pembroke

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom